Nektar Therapeutics (NKTR) Deferred Taxes (2023 - 2024)
Nektar Therapeutics (NKTR) recorded quarterly Deferred Taxes of -$31000.0 in Q3 2024, down 154.39% quarter-over-quarter from $57000.0 in Q2 2024, and down 106.67% on a YoY basis from $465000.0 in Q4 2023.
Nektar Therapeutics (NKTR) Deferred Taxes (2023 - 2024) Analysis & Trends
Nektar Therapeutics' Deferred Taxes history runs 2 years deep, the most recent figure standing at -$31000.0 for Q3 2024.
- In Q3 2024, Deferred Taxes fell 106.67% year-over-year to -$31000.0; the TTM figure through Sep 2024 stood at $1.8 million (up 199.35% YoY), while the FY2021 annual figure was -$102000.0, down 183.33% from the prior year.
- Deferred Taxes was -$31000.0 for Q3 2024 at Nektar Therapeutics, down from $57000.0 in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $1.9 million in Q4 2023 to a low of -$1.8 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -859,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -65.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Nektar Therapeutics | 1.51 Bn | 939.55 Mn | 3.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -31,000.00 |
| Jun 30, 2024 | 57,000.00 |
| Mar 31, 2024 | -38,000.00 |
| Dec 31, 2023 | 1.85 Mn |
| Sep 30, 2023 | -15,000.00 |
| Jun 30, 2023 | -27,000.00 |
| Mar 31, 2023 | -1.81 Mn |